BMY Bristol Myers Squibb Co

By Colin Kellaher

Bristol Myers Squibb Co. has won Food and Drug Administration approval for expanded use of the blockbuster arthritis drug Orencia as the first U.S. drug for the prevention of moderate-to-severe acute graft-versus-host disease.

The agency said the approval covers Orencia in combination with certain immunosuppressants for patients two years of age or older undergoing hematopoietic stem-cell transplantation from an unrelated donor.

Acute graft-versus-host disease is a potentially fatal complication that occurs when donor bone marrow or stem cells attack the graft recipient.

Bristol Myers reported revenue of $2.44 billion for the first nine months of the year for Orencia, which was previously approved in the U.S. to treat adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and adult psoriatic arthritis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 15, 2021 12:29 ET (17:29 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024